212Pb-anti-LRRC15 antibody

212Pb-anti-LRRC15 antibody is a preclinical targeted alpha therapy (TAT) radiopharmaceutical consisting of a monoclonal antibody targeting leucine-rich repeat-containing protein 15 (LRRC15) labeled with the alpha-emitting radioisotope Lead-212 (212Pb). LRRC15 is a transforming growth factor-beta (TGF-β)-driven cell surface protein highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment and on certain mesenchymal-derived cancer cells, while showing minimal expression in normal tissues. The targeting antibody (such as DUNP19 / LNTH-2403) binds to LRRC15 and is rapidly internalized. Lead-212 acts as an in vivo alpha-particle generator, decaying to produce alpha-emitting daughters (such as Bismuth-212) that deliver highly cytotoxic, localized radiation to the tumor and its supportive stroma, sparing surrounding healthy tissue. Developed by researchers at Washington University in St. Louis, this radioconjugate is being evaluated in preclinical models of colon cancer and other solid tumors.

Other names

212Pb-labeled DUNP19212Pb-labeled LNTH-2403212Pb-labeled anti-LRRC15 antibodyLead-212 anti-LRRC15 antibodyLead212 anti-LRRC15 antibodyLead 212 anti-LRRC15 antibodyLead-212 labeled DUNP19Lead212 labeled DUNP19Lead 212 labeled DUNP19Lead-212 labeled LNTH-2403Lead212 labeled LNTH-2403Lead 212 labeled LNTH-2403Lead-212 labeled anti-LRRC15 antibodyLead212 labeled anti-LRRC15 antibodyLead 212 labeled anti-LRRC15 antibodyLead-212-DUNP19Lead212-DUNP19Lead 212-DUNP19Lead-212-LNTH-2403Lead212-LNTH-2403Lead 212-LNTH-2403